Because the transition is a change in your medication regimen, side-effects or unusual responses are possible: increased heart rate, more intense nausea, possibly more rapid drop in body weight requiring nutritional adjustments
clinician review for eligibility
Because different salt forms have different molecular weights
TRIUMPH-4, the first completed Phase 3 trial, showed 28.7% average body weight loss at 68 weeks on retatrutide 12mg versus 2.1% on placebo, as reported by Eli Lilly in December 2025 (peer-reviewed publication pending)
Most patients can safely continue GLP-1 medications before colonoscopy with appropriate precautions, including a 24-hour liquid-only diet before the procedure
The GLP1/GIP dualreceptor agonist DA5CH inhibits the NFB inflammatory pathway in the MPTP mouse model of Parkinsons disease more effectively than the GLP1 singlereceptor agonist NLY01